Shares of biotech firms focused on gene editing have been heating up this month, largely on the back of the…
McAlinden Research PartnersMay 25, 2023
Pfizer's acquisition of Seagen, which is the largest biopharma deal since 2019, comes as products received in previous deals begin…
McAlinden Research PartnersMarch 14, 2023
A potential acquisition of Seagen by Pfizer, likely in the neighborhood of $40.0 billion, would be the biggest biopharma deal…
McAlinden Research PartnersFebruary 27, 2023
Throughout the past month, legislators in nearly half a dozen US states have introduced bills focused on reforming laws that…
McAlinden Research PartnersJanuary 30, 2023
Expectations for AI in healthcare, particularly biopharma and diagnostics, have been high for several years now. New partnerships and acquisitions may…
McAlinden Research PartnersJanuary 17, 2023
The biopharma industry is kicking off the year with price hikes and some early signs of a sustained uptick in…
McAlinden Research PartnersJanuary 5, 2023
Shares of biotechnology firms focused on gene editing were slammed this week by an FDA hold placed on Verve Therapeutics'…
McAlinden Research PartnersDecember 8, 2022
Three pharma giants are in the running to purchase Horizon Therapeutics in what will likely be a larger deal than…
McAlinden Research PartnersDecember 1, 2022
Mergers and Acquisitions in the biopharma space continue to heat up, fueling a significant increase in large deals through the first 9…
McAlinden Research PartnersOctober 19, 2022
